Abstract

FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLETS OF QUINAPRIL HCl USING BY VARIOUS POLYMERS

Bhukya Nagaraju*, Dr. R. Suthakaran, P. Srinivas, P. Pravararchitha Reddy, P. Renuka, A. Swathi, C. Bhavani and R. Ashwini

ABSTRACT

Most conventional oral drug products, such as tablets and capsules, are formulated to release the active drug immediately after oral administration, to obtain rapid and complete systemic drug absorption. Such immediate-release products result in relatively rapid drug absorption and onset of accompanying pharmacodynamic effects. However, after absorption of the drug from the dosage form is complete, plasma drug concentrations decline according to the drug's pharmacokinetic profile. Eventually, plasma drug concentrations fall below the minimum effective plasma concentration (MEC), resulting in loss of therapeutic activity. Before this point is reached, another dose is usually given if a sustained therapeutic effect is desired. An alternative to administering another dose is to use a dosage form that will provide sustained drug release, and therefore maintain plasma drug concentrations, beyond what is typically seen using immediate-release dosage forms. Whereas the formulations prepared with Eudragit RLPO retarded the drug release in the concentration of 100 mg showed required release pattern i.e., retarded the drug release up to 12 hours and showed maximum of 97.25% in 12 hours with good retardation. The formulations prepared with Eudragit L-100 showed more retardation even after 12 hours they were not shown total drug release. Hence, they were not considered.

Keywords: Eudragit L-100, Eudragit RLPO, Ferrous sulfate, UV-spectrophotometer, HCl.